Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "net-profit"

596 News Found

Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr
News | February 03, 2023

Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr

The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022


GMM Pfaudler posts Q3 FY23 consolidated profit at Rs. 18.67 Cr
News | February 03, 2023

GMM Pfaudler posts Q3 FY23 consolidated profit at Rs. 18.67 Cr

The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022


Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr
News | February 02, 2023

Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr

The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022


Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr
News | January 29, 2023

Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr

The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022


Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
News | January 29, 2023

Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr

The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022


Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
News | January 28, 2023

Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr

The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022


Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
News | January 27, 2023

Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022


Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr
News | January 27, 2023

Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr

The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022


Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr
News | November 14, 2022

Supriya Lifescience Q2 FY2023 profit slips to Rs. 16.86 Cr

The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore